{"id":171625,"date":"2026-09-22T06:58:27","date_gmt":"2026-09-22T06:58:27","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/171625\/"},"modified":"2026-09-22T06:58:27","modified_gmt":"2026-09-22T06:58:27","slug":"why-novo-nordisk-investors-feel-disappointed-today-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/171625\/","title":{"rendered":"Why Novo Nordisk investors feel disappointed today"},"content":{"rendered":"<p>   00:00     Speaker A <\/p>\n<p data-testid=\"typography\" class=\" type-body-md-reg    yf-gjjls9\">Now, another one I&#8217;m watching too and this comes top of mind because a couple weeks ago I had Michael Dutar uh on speaking of new CEOs on my on my podcast, Power players. and you should go check it out. It was a really good chat. I think Mike just he flung it. he flung it. He just let it fly. He just said about, you know, where we have lost market share, we need to do marketing a lot better. We need to do a better job. <\/p>\n<p>   00:27     Speaker A <\/p>\n<p data-testid=\"typography\" class=\" type-body-md-reg    yf-gjjls9\">Now, the outlook today, they came out with about a couple weeks removed from that conversation. I had, you know, I came away with that that combo thinking, well, uh, all right, well, this investor is not gonna be good. They had not gonna be good. They had a capital markets day today, disappointed on the outlook, didn&#8217;t really give uh investors any sense on short-term targets. I think investors, you&#8217;re going to see a lot of analyst notes start to trickle in today and tomorrow, worrying and calling about the company&#8217;s patent cliff. <\/p>\n<p>   01:03     Speaker A <\/p>\n<p data-testid=\"typography\" class=\" type-body-md-reg    yf-gjjls9\">I think you&#8217;re going to see some concerns expressed on the uh uptake on the new weight loss pill, which started off a little slow when it got released a couple months ago. A lot of concerns here. Now, I want to resurface this clip from when we talked to Mike on Power players about, uh, I asked him what what has been going wrong with this company? A couple years ago, this company won our company of the year. They were the dominant force in weight loss pills and weight loss shots and now pills. <\/p>\n<p>   01:41     Speaker A <\/p>\n<p data-testid=\"typography\" class=\" type-body-md-reg    yf-gjjls9\">Now Eli Lilly is crushing him. Here&#8217;s what Mike said. <\/p>\n<p>   01:46     Speaker B <\/p>\n<p data-testid=\"typography\" class=\" type-body-md-reg    yf-gjjls9\">We were a little bit ahead of our time. When we came with um Ozempic and Vigovi to the market, when you come second to market as our competitor did, it&#8217;s easier to look at the flaws and uh and improve and adjust it. <\/p>\n<p>   02:07     Speaker B <\/p>\n<p data-testid=\"typography\" class=\" type-body-md-reg    yf-gjjls9\">I would like to see a future after patent cliff where majority of semaglutide sold is sold by Novo Nordisk. Today, Novo is the biggest generic insulin maker in the world. <\/p>\n<p>   02:28     Speaker A <\/p>\n<p data-testid=\"typography\" class=\" type-body-md-reg    yf-gjjls9\">Here&#8217;s where I&#8217;m leaving this on Novo. I think you&#8217;re going to see earnings estimates continue to fall hard on Novo. You&#8217;re going to see some bearish notes come out over the next few weeks on Novo. <\/p>\n<p>   02:40     Speaker A <\/p>\n<p data-testid=\"typography\" class=\" type-body-md-reg    yf-gjjls9\">What this means, if you&#8217;re inclined to play this space, you stick with Eli Lily. Eli Lily has been taking business off of Novo. They&#8217;re the likely winner. expecting another 12 strong months for Eli Lily. You can see this uh the chart there, the disparity between these companies. Eli Lily has been the proven winner in the space for a year. And I think Novo, everything that they talked about today underscores that. Go back and read the capital markets transcript today from Novo. I think you&#8217;ll learn a hell of a lot. <\/p>\n","protected":false},"excerpt":{"rendered":"00:00 Speaker A Now, another one I&#8217;m watching too and this comes top of mind because a couple&hellip;\n","protected":false},"author":2,"featured_media":171626,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[21375,276,272],"class_list":["post-171625","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-brian-sozzi","tag-eli-lilly","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117313398839945109","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/171625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=171625"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/171625\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/171626"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=171625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=171625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=171625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}